Gentris jv brings personalised medicine to Japan
Gentris Corporation, a global provider of pharmacogenomic services and diagnostic products, has signed a partnership based on a 10-year licensing agreement with FALCO Biosystems, one of the largest publicly-traded medical testing laboratories in Japan.
Gentris Corporation, a global provider of pharmacogenomic services and diagnostic products, has signed a partnership based on a 10-year licensing agreement with FALCO Biosystems, one of the largest publicly-traded medical testing laboratories in Japan.
The partnership, to be called "Gentris Japan," will offer services to global pharmaceutical companiesbased in Japan that are looking to integrate pharmacogenomics into their drug development programmes. Japan has the second-largest pharmaceutical market in the world after the US.
"It is evident that pharmacogenomics is going to be as important to drug development, and ultimately the public, in Japan as it is in the US and Europe," said Gentris ceo Michael Murphy. "For several drugs routinely prescribed in Japan, research has identified clear relationships between individual genetic differences and how these drugs are metabolised. Gentris Japan will work to ensure that people receive safer and more effective medications, at the appropriate dosage, based on these individual genetic variations.
"By partnering with FALCO, a Japanese leader in applications of molecular biology with facilities throughout the country, we are strategically positioned to better serve our current clients while at the same time developing new relationships with global pharmaceutical companies in the market," he added.
Gentris is developing validated reference controls and diagnostic test kits designed to bring personalised medicine to physicians and patients, enhancing patient management and improving patients' response to therapy.